Omega-3 fatty acids

LOVAZA

Open Omega-3 fatty acids in the interactive console ↗

Omega-3 fatty acids ballicule: receptor binding, kinetics and half-life diagram — Mechanism of action: Omega-3 fatty acids ballicule

What it isOmega-3 fatty acid preparations activating PPAR-alpha pathways; severe hypertriglyceridemia.

Why this oneUnlike purified icosapent ethyl, mixed EPA/DHA can raise LDL and lacks proven cardiovascular outcome benefit.

What limits itFishy eructation and GI upset impair adherence; watch for atrial fibrillation and additive bleeding.

Pearls

Pancreatitis prevention unproven; only olezarsen shown to reduce it.
Dose 4 g daily with food.

Omega-3 fatty acids molecular structure (skeletal formula) — Molecular structure: Omega-3 fatty acids

Omega-3 fatty acids prescription history

Animated chart of estimated U.S. prescriptions per year, Lipid-lowering meds (1955–2026). Omega-3 fatty acids enters in 2005 (estimated).

FDA-approved for

hypertriglyceridemia (2004)

Principal riskIt can RAISE LDL, unlike icosapent ethyl

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4

Overdose danger1 / 4

Weight-gain liability0 / 4

Sedation liability0 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilityMyopathy/rhabdomyolysis and hepatotoxicity; interaction burden varies by agent.

FDA label

Read the full label on DailyMed ↗

NO BOXED WARNINGS

FDA dosing	Population	Start	Target	Max
Severe hypertriglyceridemia (TG ≥500 mg/dL), adjunct to diet	Adults	4 g QD (4 caps) or 2 g BID (2 caps BID)	4 g/day	4 g/day

Renal Undefined

Hepatic Undefined

Instructions

Swallow capsules whole — do not break open, crush, dissolve, or chew
Administered with meals in clinical studies
Start and continue an appropriate lipid-lowering diet
Before starting: assess TG level and manage secondary causes (diabetes, hypothyroidism, medications)

Available strengths

cap 1000 mg

Cautions

May increase LDL-C — monitor LDL periodically
Hepatic impairment: monitor ALT and AST periodically during therapy
Use with caution in fish and/or shellfish allergy
Possible increased recurrence of symptomatic atrial fibrillation/flutter in patients with paroxysmal or persistent AF, especially first 2-3 months; not indicated for AF/flutter
Monitor TG levels periodically during therapy

Adverse reactions

Most common (>3%, > placebo): eructation, dyspepsia, taste perversion
Also: constipation, GI disorder, vomiting, increased ALT/AST, pruritus, rash
Postmarketing: anaphylactic reaction, hemorrhagic diathesis, urticaria

Pregnancy Insufficient human data to identify drug-associated risk; animal studies showed no adverse reproductive/developmental effects at 5x MRHD

Lactation Omega-3 fatty acids (EPA/DHA) present in human milk (higher with supplementation); no data on infant effects or milk production — weigh benefit vs. risk

Cost

Omega-3 fatty acids (LOVAZA)

Strength		#/mo	generic $/mo	CostPlus
1000 mg	cap	30 qd		not offered

NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Omega-3 fatty acids is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

Generic entry2014

Open Omega-3 fatty acids in the interactive console ↗

Self-check

Omega-3 fatty acids: How can mixed EPA/DHA affect LDL?
It can raise LDL.
Omega-3 fatty acids: Does mixed EPA/DHA have proven cardiovascular outcome benefit?
No.